Mouse models of Marfan syndrome have demonstrated increased TGF-β/Smad signaling in myxomatous valve pathophysiology, consistent with a role for FBN1 in limiting TGF-β activity in the extracellular matrix (7–9). This evidence concerns the gene TGFB1 and Marfan syndrome.